| Literature DB >> 29992386 |
Yun-Fei Zhang1, Hong Li2, Xue-Mei Wang3, Yun-Fei Cai4.
Abstract
OBJECTIVES: To assess the performance of sonoelastography for differential diagnosis between malignant and benign parotid lesions using a meta-analysis.Entities:
Keywords: Elasticity imaging techniques; Parotid neoplasms; Ultrasonography
Mesh:
Year: 2018 PMID: 29992386 PMCID: PMC6302921 DOI: 10.1007/s00330-018-5609-6
Source DB: PubMed Journal: Eur Radiol ISSN: 0938-7994 Impact factor: 5.315
Search strategy of each database
| Database | Strategy |
|---|---|
| PubMed | (((((((("Parotid Neoplasms"[Mesh]) OR parotid neoplasm) OR parotid cancer) OR parotid carcinoma) OR parotid tumor) OR parotid mass) OR parotid lesion)) AND (((((((("Elasticity Imaging Techniques"[Mesh]) OR elasticity imaging technique) OR tissue elasticity imaging) OR elastography) OR vibro acoustography) OR acoustic radiation force impulse) OR sonoelastography) OR elastogram) |
| Embase and Medline ( | (#1) parotid AND neoplasm OR (parotid AND cancer) OR (parotid AND carcinoma) OR ( parotid AND tumor) OR (parotid AND mass) OR (parotid AND lesion) |
| Cochrane Library | (#1) Mesh descriptor: [Parotid Neoplasms] explode all trees |
| Web of Science | TOPIC: ((parotid neoplasm) OR (parotid cancer) OR (parotid carcinoma) OR (parotid tumor) OR (parotid mass) OR (parotid lesion)) AND TOPIC: ((elasticity imaging technique) OR (tissue elasticity imaging) OR (elastography) OR (vibro acoustography) OR (acoustic radiation force impulse) OR (sonoelastography) OR (elastogram)) |
| OVID | (#1) (parotid neoplasm OR parotid cancer OR parotid carcinoma OR parotid tumor OR parotid mass OR parotid lesion).af. |
Fig. 1Flow diagram of study selection. n = number of studies
Main characteristics of included studies
| Author | Country | Year | Age (avg. or median) | Male/female | Number of patients | Number of lesions | Reference standard | Type of lesions (number of lesions) | Ultrasound system | Index of elastography | Cut-off value | TP | FP | FN | TN | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Klintworth et al [ | Germany | 2012 | 53.3 | 27/30 | 57 | 57 | Postoperative pathology | Squamous cell carcinoma (3), mucoepidermoid carcinoma (1), salivary duct carcinoma (1), basal cell carcinoma (1), carcinoma ex pleomorphic adenoma (1), metastatic malignant melanoma (1); pleomorphic adenoma (22), Warthin tumour (20), cystadenoma (2), lipoma (2), cyst (3) | Siemens Ltd., Healthcare Sector, Acuson S2000 | Garland sign | Garland sign (+) | 3 | 2 | 5 | 47 |
| 2 | Yerli et al [ | Turkey | 2012 | 47.4 | 15/15 | 30 | 30 | Postoperative pathology ( | Adenocarcinomas (2), mucoepidermoid carcinomas (2), adenoid cystic carcinomas (1), malignant lymphoma (1); Warthin tumours (10), pleomorphic adenomas (10), lymphadenopathies (3), abscesses (1) | Hitachi Medical Systems, EUB-7000 | ES (4-point) | ES3 | 4 | 8 | 2 | 16 |
| 3 | Badea et al [ | Romania | 2013 | NA | 15/5 | 20 | 20 | postoperative pathology | Parotid carcinomas (6), metastases (2); all pleomorphic adenomas (12) | General Electric GE 7, GE 8, GE 9; Phillips, iU22; Siemens S 2000 | Tactile Elastography or ARFI | NA | 8 | 6 | 0 | 6 |
| 4 | Celebi and Mahmutoglu [ | Turkey | 2013 | 47.19 | 36/39 | 75 | 81 | Postoperative pathology ( | Lymphoma (9), mucoepidermoid carcinoma (6), adenoid cystic carcinoma (5), metastases (3), myoepithelial malignant tumour (1), pleomorphic adenocarcinoma (2), salivary duct carcinoma (2), acinic cell carcinoma (2) and basal cell carcinoma (2); pleomorphic adenoma (28), Warthin tumour (10), lymphadenopathy (9), cystic adenoma/infected cyst rupture (2) | Siemens Medical Solutions, Siemens S2000 | CSES (4-point) | CSES3 | 19 | 19 | 13 | 30 |
| 5 | Wierzbicka et al [ | Poland | 2013 | 54 | 27/16 | 43 | 43 | Postoperative pathology | Adenocarcinoma (3), malignant lymphoma (2), clear cell carcinoma (1), non-differentiated cancer (1), squamous cell cancer (1), cancer from pleomorphic adenoma (1) and salivary duct cancer (1); pleomorphic adenoma (23), Warthin tumour (5), monomorphic adenoma (2), neurofibroma (1), cyst (1), basal cell adenoma (1) | Supersonic Imagine, Aixplorer | ES (5-point) | ES4 | 4 | 1 | 6 | 32 |
| 6 | Yu et al [ | China | 2016 | 45 | NA | 51 | 51 | Postoperative pathology | Mucoepidermoid carcinomas (5), acinic cell carcinomas (3), salivary duct carcinomas (3), basal cell carcinomas (2), adenoid cystic carcinoma (1), adenocarcinoma (1), carcinoma ex pleomorphic adenoma (1); pleomorphic adenoma (16), adenolymphomas (15), basal cell adenomas (2), multiple nodular acidophil adenoma (1), myoepithelioma (1) | Siemens Medical Solutions, Acuson S2000 | SWV | 2.76 m/s | 11 | 1 | 5 | 34 |
| 7 | Altinbas et al [ | Turkey | 2017 | 60.01 | 26/20 | 46 | 54 | Fine-needle aspiration biopsy (cytological and histological results) | Malignant melanoma (3), salivary duct carcinoma (2), squamous cell carcinoma (1), adenoid cystic carcinoma (1), low-grade adenocarcinoma (1), mucoepidermoid carcinoma (1), Merkel cell carcinoma (1); Warthin tumour (18), pleomorphic adenoma (8), reactive lymphoid hyperplasia (6), lipoma (3), granulomatous inflammation (2), basal cell adenoma (2), lymphoepithelial cyst (1), sialadenitis and abscess (1), sialadenosis (1), primary benign oncocytic neoplasm (1), Rosai-Dorfman disease (1) | GE HealthCare, Logiq S7 Expert | E-index | 3 | 7 | 15 | 3 | 29 |
| 8 | Cantisani et al [ | Italy | 2017 | 56 | NA | 63 | 63 | Postoperative pathology and FNAC | Mucoepidermoid carcinoma (5), malignant lymphoma (3), squamous cell carcinoma (2), acinic cell carcinoma (2), salivary duct carcinoma (2) and squamous cell carcinoma metastasis (2); pleomorphic adenoma (18), Warthin tumour (17), oncocytoma (5), lymphoepithelial cyst (3), ductal cyst (2), benign vascular tumour (2). | Samsung Medison, Accuvix A30, RS 80 A | ECI | 3.5 | 15 | 5 | 1 | 42 |
| 9 | Herman et al [ | Czech Republic | 2017 | 60 | 66/58 | 124 | 124 | Postoperative pathology | Squamous cell carcinoma (8), low grade salivary tumour (6), high grade salivary tumour (7), lymphoma (3), melanoma (2), sarcoma (1), neuroendocrine carcinoma (1); pleomorphic adenoma (49), Warthin tumour (33), other benign lesions (14) including oncocytic adenomas, lipomas, lipomatosis, basal cell adenoma, non-sebaceous lymphadenoma, branchiogenic cyst, and chronic inflammation | SuperSonic Imagine,Aixplorer | CSV | 1025 | 18 | 17 | 10 | 79 |
| 10 | Mansour et al [ | Germany | 2017 | 58.6 | NA | 202 | 202 | Postoperative pathology | Primary parotid carcinomas (10), secondary parotid carcinomas (13), non-Hodgkin lymphomas (9); pleomorphic adenomas (64), Warthin tumours (73), basal cell adenomas (6), oncocytomas (3), polymorphic adenomas (2), myoepithelioma (1), sebaceous lymphadenoma (1), ductal dilatations (8), lymphoepithelial cysts (5), cystadenomas (4), chronic inflammations (3) | Siemens Healthcare, Acuson S2000 | ES (3-point) | ES2 | 22 | 126 | 10 | 44 |
Avg. average, FNAC fine needle aspiration cytology, SWV shear wave velocity, CSV coefficient of stiffness variability (maximum of stiffness/minimum of stiffness), CSES consensus sonoelastography scores, ES elastographic scoring, ECI elasticity contrast index, ARFI acoustic radiation force impulse, TP true positive, FN false negative, FP false positive, TN true negative, NA not available
*Missing data provided by corresponding author via e-mail
#Another study [25] from the same department was omitted
Quality assessment of the included studies using the “QUADAS” questionnaire
| QUADAS questionnaire | Klintworth et al 2012 [ | Yerli et al 2012 [ | Badea et al 2013 [ | Celebi and Mahmutoglu 2013 [ | Wierzbicka et al 2013 [ | Yu et al 2016 [ | Altinbas et al 2017 [ | Cantisani et al 2017 [ | Herman et al 2017 [ | Mansour et al 2017 [ |
|---|---|---|---|---|---|---|---|---|---|---|
| 1: Was the spectrum of patient representative of the patients who will receive the test in practice? | Yes | Yes | No | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| 2: Were selection criteria clearly described? | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| 3: Is the reference standard likely to correctly classify the target condition? | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| 4: Is the time period between reference standard and index test short enough to be sure that the target condition did not change between the two tests? | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| 5: Did the whole sample, or a random selection of the sample, receive verification using a reference standard of diagnosis? | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| 6: Did patients receive the same reference standard regardless of the index test result? | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| 7: Was the reference standard independent of the index test (i.e., the index test did not form part of the reference standard)? | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| 8: Was the execution of the index test described in sufficient detail to permit replication of the test? | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| 9: Was the execution of the reference standard described in sufficient detail to permit replication? | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| 10: Were the index test results interpreted without knowledge of the results of the reference standard? | No | Yes | Yes | Yes | Yes | Unclear | Yes | Yes | Yes | Yes |
| 11: Were the reference standard results interpreted without knowledge of the results of the index test? | Unclear | Unclear | Unclear | Unclear | Unclear | Unclear | Unclear | Unclear | Unclear | Unclear |
| 12: Were the same clinical data available when test results were interpreted as would be available when the test is used in practice? | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| 13: Were un-interpretable/intermediate test results reported? | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| 14: Were withdrawals from the study explained? | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| QUADAS score | 12.5 | 13.5 | 12.5 | 13.5 | 13.5 | 13 | 13.5 | 13.5 | 13.5 | 13.5 |
Fig. 2Forest plots of the pooled sensitivity (a) and specificity (b) of sonoelastography for differentiating between malignant and benign parotid lesions
Fig. 3Summary receiver operating characteristic (SROC) curve on sonoelastography for differentiating between malignant and benign parotid lesions. The middle curve is the SROC curve. The upper and lower curves show the 95% confidence intervals
Results of the meta-regression and subgroup analysis for differential diagnosis between malignant and benign parotid lesions
| Subgroup | Number of studies | Pooled sensitivity (95% CI) | Pooled specificity (95% CI) | Pooled DOR (95% CI) | AUC | |
|---|---|---|---|---|---|---|
| Mechanism | 0.119 | |||||
| SWE | 6 | 0.61 (0.52–0.70) | 0.62 (0.57–0.66) | 6.39 (1.82–22.35) | 0.67 | |
| SE | 3 | 0.81 (0.64–0.93) | 0.76 (0.67–0.83) | 11.67 (1.56–87.41) | 0.64 | |
| SWE technique | 0.473 | |||||
| ARFI | 4 | 0.63 (0.52–0.73) | 0.51 (0.45–0.57) | 4.91 (0.96–25.05) | 0.65 | |
| SSI | 2 | 0.58 (0.41–0.74) | 0.86 (0.79–0.92) | 9.50 (3.99–22.63) | NA | |
| Assessment method | 0.035* | |||||
| Qualitative | 5 | 0.59 (0.48–0.69) | 0.52 (0.46–0.58) | 3.38 (1.08–10.57) | 0.63 | |
| Qualitative or semiquantitative | 4 | 0.73 (0.61–0.83) | 0.83 (0.77–0.88) | 18.64 (4.51–77.07) | 0.88 | |
| QUADAS score | 0.462 | |||||
| 13.5 | 7 | 0.66 (0.58–0.74) | 0.59 (0.54–0.63) | 5.41 (1.81–16.13) | 0.74 | |
| ≤ 13 | 3 | 0.69 (0.50–0.84) | 0.91 (0.83–0.96) | 26.56 (6.91–102.11) | 0.90 |
SE strain elastography, SWE shear wave elastography, SSI supersonic shear imaging, ARFI acoustic radiation force impulse imaging, NA not available
*Meta-regression, p < 0.05
Fig. 4Funnel plot for evaluating potential publication bias. Each solid circle represents a study in the meta-analysis. The line is the regression line